Latest press releases

01-Jul-25

Comment on CMS proposed rule change issued 30 June 2025

26-Jun-25

Convatec welcomes regulatory approval of subcutaneous apomorphine infusion for advanced Parkinson’s disease in the US

22-May-25

AGM trading update for the four months ended 30 April 2025

20-May-25

Advancing subcutaneous infusion therapy for patients through innovation and partnerships

25-Apr-25

Convatec receives regulatory approval for ConvaNiox™

11-Apr-25

Convatec welcomes postponement of Local Coverage Determinations (LCDs) on skin substitutes until January 2026

31-Mar-25

Convatec announces exclusive collaboration with largest Wound, Ostomy and Continence professional nursing organisation

18-Mar-25

Convatec showcases its strongest wound care innovation pipeline ever at EWMA

26-Feb-25

Annual results for the year ended 31 December 2024

26-Jan-25

Convatec welcomes the postponement of Local Coverage Determinations (LCDs) on skin substitutes in the United States

16-Dec-24

Convatec unveils new resources to support intermittent catheter users to live life confidently

14-Nov-24

Convatec responds to Local Coverage Determinations (LCDs) on skin substitutes in the United States

12-Nov-24

Trading update for the ten months ended 31 October 2024

21-Oct-24

Convatec collaborates with AbbVie for VYALEV™ therapy for the treatment of advanced Parkinson’s disease in the United States

10-Oct-24

Convatec update on InnovaMatrix® AC clinical data – second randomised controlled trial authorised

20-Sep-24

Convatec update on InnovaMatrix® AC clinical data